A complete application in a minute
Tailored resume and cover letter, ready to send.
Zealand Pharma U.S., Inc. seeks a Senior Director of Field Medical Affairs – Obesity to lead the national obesity-focused MSL organization through two regional directors.
You will translate scientific strategy into field impact, coordinating with Medical, Clinical Development, and Commercial teams to drive KOL engagement and launch readiness for obesity assets. The role requires a proven track record in leading leaders, building high-performing field teams, and navigating US regulatory and
Does it excite you to lead a national field medical organization at the forefront of obesity and metabolic disease, and do you bring seasoned Medical Affairs experience leading leaders? If this sounds like you, and you are ready to take on a broad area of responsibilities, then you could be our new colleague.
As Senior Director, Field Medical Affairs – Obesity, you will lead our national obesity-focused field medical organization through two regional Field Directors (East and West), shaping how we translate scientific strategy into field impact. You'll be a senior voice across US Medical Affairs, Clinical Development, and Commercial, driving KOL engagement and launch readiness for our obesity and metabolic pipeline. This is a role for an experienced leader of leaders ready to build, scale, and elevate a high-performing field team.
The Senior Director, Field Medical Affairs – Obesity, reports directly to Gabe Smolarz, VP of US Medical Affairs, and leads the field-based Medical Affairs presence for Zealand Pharma's obesity/metabolic health franchise. Two regional Field Directors (East and West) report into this role, each overseeing a portion of the combined MSL team, split geographically by territory. This role sits within a growing US Medical Affairs organization built to support the petrelintide launch, alongside Medical Information, Scientific Communications, and Medical Operations functions. The Senior Director partners closely with US Medical Affairs leadership, Global Medical Affairs, and cross-functional launch teams to ensure consistent scientific engagement and field medical strategy execution nationally.
We have a unique biotech culture, characterized by excellent teamwork and strong engagement across the organization. And we want you to help us strengthen this culture. Making bonds is at the core of everything we do. From discovering and developing the best new peptide drugs for patients, to engaging with our partners or connecting with each other. We bond through curiosity and playfulness as a team, allowing ourselves to challenge common thinking and drive future innovation. Join us and let’s bond and be bold.
We are committed to an inclusive recruitment process and welcome applications from all job applicants.
Zealand Pharma A/S (Nasdaq: ZEAL) is a biotechnology company focused on advancing medicines for obesity and metabolic health. Combining more than 25 years of peptide R&D expertise with a proprietary data platform that leverages advanced data-driven and AI/ML approaches, Zealand Pharma aims to lead a new era in obesity and metabolic health. To date, more than ten Zealand Pharma-invented drug candidates have entered clinical development, of which two products have reached the market and three candidates are in late-stage development. The Company has collaborations with global pharmaceutical and biotechnology partners for research, development, and commercialization. Founded in 1998, Zealand Pharma is headquartered in Copenhagen, Denmark, with a U.S. presence in Cambridge, Massachusetts. Learn more at www.zealandpharma.com.
Since our founding in 1998, Zealand Pharma has built a core expertise in the discovery, design, and development of therapeutic peptides. This expertise has led to an R&D pipeline of innovative investigational candidates designed to address a broad range of disease areas. We have four therapeutic focus areas: obesity, rare diseases, chronic inflammation, and type 1 diabetes. In obesity, our peptide capabilities place us in a unique position to address a vast global health challenge and positively impact hundreds of millions of lives. Within rare diseases, we have a long-standing commitment to deliver new treatments to patients living with congenital hyperinsulinism and short bowel syndrome. For chronic inflammatory diseases, we are progressing peptide programs focused on high-profile targets shown to be difficult to address with small molecules and antibodies. For type 1 diabetes, we aspire to change the management of this disease. Our strategy is to pursue global co‑development and commercialization partnerships that complement and extend our capabilities across the value chain to deliver new peptide therapies to people who need them.